Skip to search boxSkip to navigationSkip to main content

TAK1 is required for TGF-β1-mediated regulation of matrix metalloproteinase-9 and metastasis

  • A. Safina
    ,
  • M. Q. Ren
    ,
  • E. Vandette
    ,
  • A. V. Bakin(corresponding author)
*Corresponding author for this work
  • Roswell Park Cancer Institute
Scholary Output:
Contribution to journal
Article
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Transforming growth factor-β 1 (TGF-β1) signaling in tumor cells has been implicated in tumor angiogenesis and metastasis by regulating matrix proteolysis. Although MMP-9/gelatinase-B is an important component of these TGF-β1 responses, the mechanism of its regulation is not well understood. Here, we present evidence that TGF-β-activated protein kinase 1 (TAK1) is critical for TGF-β regulation of MMP-9 and the metastatic potential of breast cancer cell line MDA-MB-231. We found that suppression of TAK1 signaling by dominant-negative (dn) TAK1 or RNA interference (siRNA) reduces expression of MMP-9 and tumor cell invasion, without growth inhibition in cell culture. The orthotopic xenograft studies in SCID mice showed that suppression of TAK1 signaling by dn-TAK1 reduces tumor growth and formation of lung metastases. Dn-TAK1 reduced the proliferation Ki-67 index and neovasculature of orthotopic xenografts. TAK1-mediated regulation of MMP-9 involves NF-κB signaling. Dn-TAK1 reduces NF-κB transcriptional response and inhibition of NF-κB reduces expression of MMP-9 and activity of the MMP-9 promoter reporter. Together, these findings suggest that TAK1 contributes to TGF-β1-mediated tumor angiogenesis and metastasis via a mechanism involving the TAK1-NF-κB-MMP-9 pathway.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 1198-1207 (10 pages)

Journal (Volume, Issue Number)

Oncogene (Volume 27, Issue 9)

Publication milestones

  • Published - 02/21/2008

Publication status

Published - 02/21/2008

ISSN

0950-9232

Publication IDs

  • Scopus: 39749195549
  • PubMed: 17828308

Publication metrics

Metrics

SciVal
citations
68
SciVal
FWCI
0.87
SciVal
Author count
4
SciVal
Paper percentile
92
SciVal
Top percentile
10
Fractional count
1
Fractional count
0.25
Fractional count
3
Fractional count
0.75
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Citation count
74
Mentions
1
Captures
51

Funding Details

We thank Hiroaki Sakurai and Jackie Bromberg for providing reagents; Heinz Baumann for critical reading of the manuscript; Mary M Vaughan and Karoly Toth for assistance with the immunohistochemistry and histopathology. This work was supported by PHS grant R01 CA95263 and USAMRMC grant DAMD17-02-01-0602 (to AVB) and in part by the Roswell Park Cancer Institute Cancer Center Support Grant CA 16056.
FundersFunding numbers
PHS
R01 CA95263
NCI
P30CA016056
MRMC
DAMD17-02-01-0602
RPCI
-